MEDI2070

AstraZeneca hands off another Amgen-partnered drug in a $1.5B deal with an acquisitive Allergan
Endpoints
Mon, 10/3/16 - 10:09 am
AstraZeneca
Amgen
Allergan
MEDI2070
ulcerative colitis
Crohn's Disease